High Affinity Nerve Growth Factor Receptor - Pipeline Review, H1 2017

  • ID: 4311819
  • Report
  • 99 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Allergan Plc
  • Astellas Pharma Inc
  • Dompe Farmaceutici SpA
  • Ignyta Inc
  • Merck & Co Inc
  • Proximagen Ltd
  • MORE
High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Pipeline Review, H1 2017

Summary:

High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Tropomyosin receptor kinase A or high affinity nerve growth factor receptor is a protein encoded by the NTRK1 gene. High affinity receptor for NGF bind and be activated by NTF3/neurotrophin-3. Upon dimeric NGF ligand-binding undergoes homodimerization, autophosphorylation and activation. It phosphorylates and/or activates several downstream effectors including SHC1, FRS2, SH2B1, SH2B2 and PLCG1 that regulate distinct overlapping signaling cascades driving cell survival and differentiation.

High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) pipeline Target constitutes close to 24 molecules. Out of which approximately 22 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 5, 2, 7 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Oncology, Immunology, Dermatology, Ophthalmology and Metabolic Disorders which include indications Osteoarthritis Pain, Breast Cancer, Colorectal Cancer, Pain, Solid Tumor, Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Atopic Dermatitis, Bile Duct Cancer (Cholangiocarcinoma), Brain Cancer, Central Nervous System (CNS) Tumor, Inflammatory Pain, Keratoconjunctivitis sicca (Dry Eye), Melanoma, Neuroblastoma, Neuroendocrine Tumors, Non-Small Cell Lung Cancer, Papillary Thyroid Cancer, Pruritus, Salivary Gland Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Anaplastic Large Cell Lymphoma (ALCL), Astrocytoma, Biliary Tumor, Chronic Pain, Colon Cancer, Corneal Ulcer (Ulcerative Keratitis/ Eyesore), Diabetic Retinopathy, Fibrosarcoma, Glioblastoma Multiforme (GBM), Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Inflammation, Kidney Cancer (Renal Cell Cancer), Low Back Pain, Lung Cancer, Metastatic Adenocarcinoma of The Pancreas, Metastatic Colorectal Cancer, Metastatic Melanoma, Neuropathic Pain, Non-Small Cell Lung Carcinoma, Open-Angle Glaucoma, Ovarian Cancer, Pancreatic Cancer, Persistent Corneal Epithelial Defects, Plaque Psoriasis (Psoriasis Vulgaris), Pontine Glioma, Prostate Cancer, Psoriasis, Renal Cell Carcinoma, Retinitis Pigmentosa (Retinitis), Sarcomas, Soft Tissue Sarcoma, Tenosynovial Giant Cell Tumor, Thymic Carcinoma and Thyroid Cancer.

The latest report High Affinity Nerve Growth Factor Receptor - Pipeline Review, H1 2017, outlays comprehensive information on the High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviewsalso reviews key players involved in High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1)
  • The report reviews High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) targeted therapeutics
Reasons to Buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Allergan Plc
  • Astellas Pharma Inc
  • Dompe Farmaceutici SpA
  • Ignyta Inc
  • Merck & Co Inc
  • Proximagen Ltd
  • MORE
  1. Introduction
  2. High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Overview
  3. High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Therapeutics Development
  4. Products under Development by Stage of Development
  5. Products under Development by Therapy Area
  6. Products under Development by Indication
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Therapeutics Assessment
  10. Assessment by Mechanism of Action
  11. Assessment by Route of Administration
  12. Assessment by Molecule Type
  13. High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Companies Involved in Therapeutics Development
  14. Allergan Plc
  15. Array BioPharma Inc
  16. Astellas Pharma Inc
  17. AstraZeneca Plc
  18. Daiichi Sankyo Company Ltd
  19. Dompe Farmaceutici SpA
  20. Genzyme Corp
  21. Ignyta Inc
  22. Loxo Oncology Inc
  23. Merck & Co Inc
  24. Nerviano Medical Sciences Srl
  25. Plexxikon Inc
  26. Proximagen Ltd
  27. Purdue Pharma LP
  28. Rottapharm Biotech Srl
  29. Tiziana Life Sciences Plc
  30. High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Drug Profiles
  31. AR-523 - Drug Profile
  32. Product Description
  33. Mechanism Of Action
  34. R&D Progress
  35. ARRY-954 - Drug Profile
  36. Product Description
  37. Mechanism Of Action
  38. R&D Progress
  39. ASP-7962 - Drug Profile
  40. Product Description
  41. Mechanism Of Action
  42. R&D Progress
  43. AZ-64 - Drug Profile
  44. Product Description
  45. Mechanism Of Action
  46. R&D Progress
  47. AZD-7451 - Drug Profile
  48. Product Description
  49. Mechanism Of Action
  50. R&D Progress
  51. BNN-27 - Drug Profile
  52. Product Description
  53. Mechanism Of Action
  54. R&D Progress
  55. cenegermin - Drug Profile
  56. Product Description
  57. Mechanism Of Action
  58. R&D Progress
  59. CRB-0089 - Drug Profile
  60. Product Description
  61. Mechanism Of Action
  62. R&D Progress
  63. DS-6051 - Drug Profile
  64. Product Description
  65. Mechanism Of Action
  66. R&D Progress
  67. entrectinib - Drug Profile
  68. Product Description
  69. Mechanism Of Action
  70. R&D Progress
  71. GZ-389988 - Drug Profile
  72. Product Description
  73. Mechanism Of Action
  74. R&D Progress
  75. larotrectinib - Drug Profile
  76. Product Description
  77. Mechanism Of Action
  78. R&D Progress
  79. milciclib - Drug Profile
  80. Product Description
  81. Mechanism Of Action
  82. R&D Progress
  83. Monoclonal Antibody to Inhibit TrkA for Central Nervous System Disorders and Peripheral Nervous System Disorders - Drug Profile
  84. Product Description
  85. Mechanism Of Action
  86. R&D Progress
  87. NMSP-626 - Drug Profile
  88. Product Description
  89. Mechanism Of Action
  90. R&D Progress
  91. PLX-7486 - Drug Profile
  92. Product Description
  93. Mechanism Of Action
  94. R&D Progress
  95. Small Molecule to Inhibit TrkA for Inflammatory Pain - Drug Profile
  96. Product Description
  97. Mechanism Of Action
  98. R&D Progress
  99. Small Molecules to Agonize TrkA and TrkB for Alzheimer’s Disease - Drug Profile
  100. Product Description
  101. Mechanism Of Action
  102. R&D Progress
  103. Small Molecules to Inhibit TRK1 for Pain - Drug Profile
  104. Product Description
  105. Mechanism Of Action
  106. R&D Progress
  107. SNA-120 - Drug Profile
  108. Product Description
  109. Mechanism Of Action
  110. R&D Progress
  111. SNA-125 - Drug Profile
  112. Product Description
  113. Mechanism Of Action
  114. R&D Progress
  115. Synthetic Peptide Agonize TrkA and TrkB Alzheimer's Disease and Amyotrophic Lateral Sclerosis - Drug Profile
  116. Product Description
  117. Mechanism Of Action
  118. R&D Progress
  119. tavilermide hydrochloride - Drug Profile
  120. Product Description
  121. Mechanism Of Action
  122. R&D Progress
  123. VM-902A - Drug Profile
  124. Product Description
  125. Mechanism Of Action
  126. R&D Progress
  127. High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Dormant Products
  128. High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Discontinued Products
  129. High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Product Development Milestones
  130. Featured News & Press Releases
  131. May 23, 2017: Dompe Receives Positive CHMP Opinion in Europe For Oxervate (Cenegermin Eye Drops) For the Treatment of Adult Patients with Moderate or Severe Neurotrophic Keratitis
  132. May 19, 2017: The European Medicines Agency: New medicine for rare eye disease
  133. May 17, 2017: Loxo Oncology Announces Details of Two Larotrectinib Clinical Data Oral Presentations at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
  134. May 15, 2017: Ignyta Granted Breakthrough Therapy Designation for Entrectinib by U.S. Food and Drug Administration
  135. May 12, 2017: Loxo Oncology Announces FDA Orphan Drug Designation Granted to Larotrectinib for the Treatment of Solid Tumors with NTRK-Fusion Proteins
  136. Apr 27, 2017: Ignyta Updates Progress towards Entrectinib Dual TRK and ROS1 NDA Submissions
  137. Apr 24, 2017: Tiziana Life Sciences Announces Approval of a Phase II Clinical Trial Protocol for Milciclib in Patients with Hepatocellular Carcinoma
  138. Apr 24, 2017: Ignyta to Host Conference Call and Webcast Update on Entrectinib Program and STARTRK-2 on April 27,
  139. Apr 21, 2017: Tiziana Life Sciences Announces Publication of Peer-Reviewed Paper from Positive Clinical Trial of Milciclib in Patients with Refractory Solid Tumors
  140. Apr 05, 2017: Loxo Oncology Announces Acceptance of Larotrectinib Oral Presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting
  141. Apr 04, 2017: Ignyta Announces New Data on Entrectinib at the 2017 AACR Annual Meeting
  142. Mar 31, 2017: Loxo Oncology Announces Proof of Concept Clinical Data for Larotrectinib in TRK Fusion Glioblastoma Presented at the AACR Annual Meeting
  143. Mar 30, 2017: Ignyta Announces Peer-Reviewed Publication of Activity of a TRK Inhibitor in a Primary Brain Tumor: Successful Treatment of Glioneuronal Tumor With Pan-TRK, CNS-Active Inhibitor Entrectinib Published in Precision Oncology
  144. Mar 28, 2017: Ignyta Announces Presentation of Entrectinib at the 2017 AACR Annual Meeting
  145. Mar 03, 2017: Angsana's RNA-based fusions cancer panel selected for Ignyta's STARTRK2 clinical trial in Asia-Pacific
  146. Appendix
  147. Methodology
  148. Coverage
  149. Secondary Research
  150. Primary Research
  151. Expert Panel Validation
  152. Contact Us
  153. Disclaimer
List of Tables:
  1. Number of Products under Development by Stage of Development, H1
  2. Number of Products under Development by Therapy Areas, H1
  3. Number of Products under Development by Indications, H1
  4. Number of Products under Development by Indications, H1 2017 (Contd..1), H1
  5. Number of Products under Development by Indications, H1 2017 (Contd..2), H1
  6. Number of Products under Development by Companies, H1
  7. Products under Development by Companies, H1
  8. Products under Development by Companies, H1 2017 (Contd..1), H1
  9. Products under Development by Companies, H1 2017 (Contd..2), H1
  10. Products under Development by Companies, H1 2017 (Contd..3), H1
  11. Products under Development by Companies, H1 2017 (Contd..4), H1
  12. Number of Products under Investigation by Universities/Institutes, H1
  13. Products under Investigation by Universities/Institutes, H1
  14. Number of Products by Stage and Mechanism of Actions, H1
  15. Number of Products by Stage and Route of Administration, H1
  16. Number of Products by Stage and Molecule Type, H1
  17. Pipeline by Allergan Plc, H1
  18. Pipeline by Array BioPharma Inc, H1
  19. Pipeline by Astellas Pharma Inc, H1
  20. Pipeline by AstraZeneca Plc, H1
  21. Pipeline by Daiichi Sankyo Company Ltd, H1
  22. Pipeline by Dompe Farmaceutici SpA, H1
  23. Pipeline by Genzyme Corp, H1
  24. Pipeline by Ignyta Inc, H1
  25. Pipeline by Loxo Oncology Inc, H1
  26. Pipeline by Merck & Co Inc, H1
  27. Pipeline by Nerviano Medical Sciences Srl, H1
  28. Pipeline by Plexxikon Inc, H1
  29. Pipeline by Proximagen Ltd, H1
  30. Pipeline by Purdue Pharma LP, H1
  31. Pipeline by Rottapharm Biotech Srl, H1
  32. Pipeline by Tiziana Life Sciences Plc, H1
  33. Dormant Products, H1
  34. Dormant Products, H1 2017 (Contd..1), H1
  35. Dormant Products, H1 2017 (Contd..2), H1
  36. Discontinued Products, H1
  37. Discontinued Products, H1 2017 (Contd..1), H1
List of Figures:
  1. Number of Products under Development by Stage of Development, H1
  2. Number of Products under Development by Therapy Areas, H1
  3. Number of Products under Development by Top 10 Indications, H1
  4. Number of Products by Mechanism of Actions, H1
  5. Number of Products by Stage and Mechanism of Actions, H1
  6. Number of Products by Routes of Administration, H1
  7. Number of Products by Stage and Routes of Administration, H1
  8. Number of Products by Molecule Types, H1
  9. Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Allergan Plc
  • Array BioPharma Inc
  • Astellas Pharma Inc
  • AstraZeneca Plc
  • Daiichi Sankyo Company Ltd
  • Dompe Farmaceutici SpA
  • Genzyme Corp
  • Ignyta Inc
  • Loxo Oncology Inc
  • Merck & Co Inc
  • Nerviano Medical Sciences Srl
  • Plexxikon Inc
  • Proximagen Ltd
  • Purdue Pharma LP
  • Rottapharm Biotech Srl
  • Tiziana Life Sciences Plc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll